


Highly Stereoselective Synthesis of Cyclopropylphosphonates Catalyzed by Chiral Ru(II)-Pheox Complex

Soda Chanthamath, Seiya Ozaki, Kazutaka Shibatomi, and Seiji Iwasa*

Department of Environmental and Life Sciences, Toyohashi University of Technology, 1-1 Hibarigaoka, Tempaku-cho, Toyohashi 441-8580, Japan

Supporting Information

ABSTRACT: Ru(II)-Pheox-catalyzed asymmetric cyclopropanation of diethyl diazomethylphosphonate with alkenes, including α,β -unsaturated carbonyl compounds, afforded the corresponding optically active cyclopropylphosphonates in high yields and with excellent diastereoselectivity (up to 99:1) and enantioselectivity (up to 99% ee).



Optically active cyclopropylphosphonate derivatives are important units and found in useful biologically active natural products or pharmacologically interesting compounds such as an analogue of nucleotide **1**,¹ an intermediate for HCV NS3 protease inhibitor **2**,² an analogue of L-Glu **3**,³ and an analogue of fosmidomycin **4**⁴ (Figure 1). Moreover, cyclopropylphosphonates are also convenient intermediates for the synthesis of alkylidenecyclopropane derivatives by the Wadsworth–Emmons reaction.⁵




Figure 1. Examples of biologically relevant cyclopropylphosphonate derivatives.

Among the few methods developed for the synthesis of optically active cyclopropylphosphonate derivatives,^{1–4,6} the catalytic asymmetric cyclopropanation of alkenes with diazomethylphosphonates is the most efficient method from a stereoselective synthesis perspective. Over the past decade, efficient catalytic systems have been developed using chiral Cu(I),⁷ Rh(II),⁸ and Ru(II)⁹ catalysts to afford the corresponding cyclopropylphosphonates in good yields and with high diastereo- and enantioselectivity. However, the bulkiness of the diazomethylphosphonate moiety was found

to be an important factor in providing high diastereocontrol, and the cyclopropanation of diazomethylphosphonate with electron-deficient alkenes such as α,β -unsaturated carbonyl compounds has not been reported yet. Herein, we report a highly stereoselective synthesis of cyclopropylphosphonates by the catalytic asymmetric cyclopropanation of simple diethyl diazomethylphosphonate with various alkenes, including α,β -unsaturated carbonyl compounds, catalyzed by a Ru(II)-Pheox complex.

Recently, we reported that the complex, Ru(II)-Pheox, is extremely efficient in carbene transfer reactions, particularly cyclopropanation and N–H insertion reactions.¹⁰ Therefore, we attempted the cyclopropanation of styrene **5a** with diethyl diazomethylphosphonate **6** in the presence of the Ru(II)-Pheox catalyst and first optimized the reaction conditions (Table 1).

The cyclopropanation reaction of the simple diethyl diazomethylphosphonate **6** proceeded smoothly at room temperature in various solvents to afford the corresponding cyclopropylphosphonate **7** in an excellent *trans/cis* ratio (99:1 in most cases) and with high enantioselectivity (94–98% ee) (Table 1, entries 1–6). The cyclopropanation in toluene and CH₃OH afforded low yields of the desired product due to the formation of the dimer from the diazo compound and an O–H insertion compound as the byproducts, respectively (Table 1, entries 2 and 5). Conducting the reaction at a lower temperature afforded lower yields and diastereoselectivity (Table 1, entries 6–8). The catalyst loading could be decreased to 1 mol %; however, the yield of **7** slightly decreased (Table 1, entry 9).

With the optimal reaction conditions in hand, we further studied the generality of the asymmetric cyclopropanation of

Received: April 19, 2014

Table 1. Optimization of Reaction Conditions^a

entry	solvent	temp [°C]	yield ^b [%]	trans/cis ^c	ee ^d [%]	trans
1	THF	rt	81	96:4	97	
2	toluene	rt	43	99:1	94	
3	acetone	rt	79	99:1	98	
4	dioxane	rt	81	99:1	97	
5	CH ₃ OH	rt	36	99:1	97	
6	CH ₂ Cl ₂	rt	93	99:1	97	
7	CH ₂ Cl ₂	0	93	98:2	97	
8	CH ₂ Cl ₂	-10	78	98:2	97	
9 ^e	CH ₂ Cl ₂	rt	67	99:1	97	

^aReaction conditions: styrene (1 mmol) and diethyl diazomethylphosphonate (0.2 mmol) in the presence of Ru(II)-Pheox (3 mol %) under Ar. ^bIsolated yield. ^cDetermined by NMR. ^dDetermined by chiral HPLC analysis. ^eWith 1 mol % of catalyst.

various styrene derivatives in the presence of the chiral Ru(II)-Pheox catalyst. As summarized in Table 2, styrene derivatives bearing an electron-donating group such as methyl or methoxy

Table 2. Ru(II)-Pheox Catalyzed Asymmetric Cyclopropanation of Various Alkenes with Diethyl Diazomethylphosphonate^a

entry	R	7 yield ^b [%]	trans/cis ^c	ee ^d [%]	trans
1		93 7a	99:1	97	
2		87 7b	99:1	98	
3		92 7c	98:2	97	
4		87 7d	99:1	96	
5		84 7e	98:2	98	
6		92 7f	98:2	99	
7		72 7g	62:38	99	
8		84 7h	93:7	98	
9		79 7i	99:1	94	

^aReaction conditions: alkenes 5 (1 mmol) and diethyl diazomethylphosphonate 6 (0.2 mmol) in the presence of catalyst (3 mol %) under Ar. ^bIsolated yield. ^cDetermined by NMR. ^dDetermined by chiral HPLC analysis.

could also be easily cyclopropanated to afford the desired cyclopropane products in high yields and with high diastereo- and enantioselectivity (Table 2, entries 2–4). Moreover, the cyclopropanation of styrene derivatives bearing an electron-withdrawing group such as chloro and nitro was also investigated (Table 2, entries 5 and 6). Interestingly, the enantioselectivity could be increased to 99% ee, while the diastereoselectivity decreased slightly to 98:2 dr. The cyclopropanation of α -methylstyrene smoothly afforded the corresponding cyclopropylphosphonate in a high yield and with high enantioselectivity (Table 2, entry 7). However, the diastereoselectivity was lower compared to that of the styrene without a substituent at the α -position. Vinylamine derivatives could also be cyclopropanated under the same reaction conditions to afford the corresponding 2-amino cyclopropylphosphonates in high yields and with high diastereo- and enantioselectivity (Table 2, entries 8 and 9).^{10b,e} We also examined the cyclopropanation of inner alkenes such as *trans*-2-hexene and *cis*-2-hexene; however, no cyclopropane products were observed due to the formation of a dimer from the diazo compound.

Encouraged by the results obtained with the styrene and vinylamine derivatives, we next turned our attention to the cyclopropanation of diethyl diazomethylphosphonate with electron-deficient alkenes such as α,β -unsaturated esters, ketones, and amides (Table 3). Surprisingly, the reaction with

Table 3. Ru(II)-Pheox Catalyzed Asymmetric Cyclopropanation of Various α,β -Unsaturated Carbonyl Compounds with Diethyl Diazomethylphosphonate^a

entry	5	7 yield ^b [%]	trans/cis ^c	trans ee ^d [%]
1		65 7j	99:1	98
2		87 7k	98:2	98
3		71 7l	99:1	98
4		33 7m	98:2	78
5		40 7n	98:2	87


^aReaction conditions: alkenes 5 (1 mmol) and diethyl diazomethylphosphonate 6 (0.2 mmol) in the presence of catalyst (3 mol %) under Ar. ^bIsolated yield. ^cDetermined by NMR. ^dDetermined by chiral HPLC analysis. Bn = benzyl.

phenyl acrylate afforded cyclopropane product 7j in 65% yield and with an excellent *trans/cis* ratio (99/1) and enantioselectivity (98% ee). Moreover, 1-phenylprop-2-en-1-one and *N*-phenylacrylamide could also be cyclopropanated to afford the corresponding products, 7k and 7l, in high yields and with high diastereo- and enantioselectivity (Table 3, entries 2 and 3). Although the reaction was sensitive to the *N*-substituents of acrylamides in terms of the yield (Table 3, entries 4 and 5), to

the best of our knowledge, this is the first example of the catalytic asymmetric cyclopropanation of diazomethylphosphonate with electron-deficient alkenes.

To determine the absolute configuration of cyclopropylphosphonates obtained using this catalytic system, we decided to synthesize a known compound, diethyl-2-(butyl)cyclopropylphosphonate **7o**, by carrying out the Ru(II)-Pheox-catalyzed cyclopropanation of diethyl diazomethylphosphonate with hex-1-ene **5o** (Scheme 1). The (1*R*,2*R*) configuration was


Scheme 1. Determination of Absolute Configuration of Diethyl-2-(butyl)cyclopropylphosphonate **7o**



confirmed by a comparison of the optical rotation value reported in the literature.¹¹ Interestingly, although a normal alkene **5o** was used as the substrate, highly stereoselective cyclopropanation could also be achieved (*trans/cis* = 99:1).

Finally, to demonstrate the utility of our highly stereoselective cyclopropylphosphonate synthesis, we prepared a key intermediate in the reported synthesis of the analogue of nucleotide **1** and L-Glu **3** (Scheme 2). The optically active

Scheme 2. Preparation of (–)-Diethyl-2-(hydroxymethyl)cyclopropylphosphonate **8, a Key Intermediate in the Synthesis of Analogue of Nucleotide **1** and L-Glu **3****



cyclopropylphosphonate **7p** was readily synthesized by the cyclopropanation of diethyl diazomethylphosphonate with ethyl acrylate **5p** in 78% yield and with high diastereoselectivity (99:1 dr). The reaction of **7p** with 2 equiv of LiBH_4 and 6 equiv of MeOH in THF afforded the desired product, (–)-diethyl-2-(hydroxymethyl)cyclopropylphosphonate **8**, in 86% yield and with excellent diastereoselectivity (99:1 dr) and enantioselectivity (98% ee).¹² This novel synthetic route represents a significant improvement in terms of fewer steps

and the diastereo- and enantioselectivity efficiency reported until now.^{1,3,14}

In conclusion, we developed the highly stereoselective cyclopropanation of alkenes with diethyl diazomethylphosphonate by using the Ru(II)-Pheox complex as the catalyst. Moreover, the cyclopropanation of electron-deficient alkenes such as α,β -unsaturated ester, ketone, and amides could be carried out smoothly under mild reaction conditions to afford the corresponding cyclopropylphosphonate products in high yields and with excellent diastereo- and enantioselectivity. Furthermore, this method confirms the synthetic value of (–)-diethyl-2-(hydroxymethyl)cyclopropylphosphonate **8**, a key intermediate in the synthesis of the analogue of nucleotide **1** and L-Glu **3**. This efficient procedure can contribute to the progress of synthetic organic chemistry.

■ ASSOCIATED CONTENT

Supporting Information

Experimental procedures and characterization data of all the new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: iwasa@ens.tut.ac.jp.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientific Research (C) (No. 23550179) from the Japan Society for the Promotion of Science.

■ REFERENCES

- (1) Midura, W. H.; Krysiak, J. A.; Mikołajczyk, M. *Tetrahedron: Asymmetry* **2003**, *14*, 1245–1249.
- (2) Pyun, H.-J.; Clarke, M. O.; Cho, A.; Casarez, A.; Ji, M.; Fardis, M.; Pastor, R.; Sheng, X. C.; Kim, C. U. *Tetrahedron Lett.* **2012**, *53*, 2360–2363.
- (3) Midura, W. H.; Krysiak, J.; Rzewnicka, A.; Supel, A.; Łyżwa, P.; Ewas, A. M. *Tetrahedron* **2013**, *69*, 730–737.
- (4) Devreux, V.; Wiesner, J.; Goeman, J. L.; Eycken, J. V.; Jomaa, H.; Calenbergh, S. V. *J. Med. Chem.* **2006**, *49*, 2656–2660.
- (5) Lewis, R. T.; Motherwell, W. B. *Tetrahedron Lett.* **1988**, *29*, 5033–5036.
- (6) The method for the synthesis of racemic cyclopropylphosphonates: (a) Hirao, T.; Hagihara, M.; Ohshiro, Y.; Agawa, T. *Synthesis* **1984**, *1*, 60–61. (b) Dappen, M. S.; Pellicciari, R.; Natalini, B.; Monahan, J. B.; Chiorri, C.; Cordi, A. A. *J. Med. Chem.* **1991**, *34*, 161–168. (c) Lewis, R. T.; Motherwell, W. B.; Shipman, M.; Slawin, A. M. Z.; Williams, D. J. *Tetrahedron* **1995**, *51*, 3289–3302. (d) Yan, Z.; Zhou, S.; Kern, E. R.; Zemlicka, J. *Tetrahedron* **2006**, *62*, 2608–2615. (e) Davi, M.; Lebel, H. *Chem. Commun.* **2008**, 4974–4976. (f) Krawczyk, H.; Wasek, K.; Kedzia, J.; Wojciechowski, J.; Wolf, W. M. *Org. Biomol. Chem.* **2008**, *6*, 308–318. (g) Amori, L.; Serpi, M.; Marinozzi, M.; Costantino, G.; Diaz, M. G.; Mermitt, M. B.; Thomsen, C.; Pellicciari, R. *Dokl. Akad. Nauk* **2013**, *450*, 547–552. The method for the synthesis of optically active cyclopropylphosphonates: (h) Maux, P. L.; Abrunhosa, I.; Berchel, M.; Simonneaux, G.; Gulea, M.; Masson, S. *Tetrahedron: Asymmetry* **2004**, *15*, 2569–2573. (i) Amori, L.; Serpi, M.; Marinozzi, M.; Costantino, G.; Diaz, M. G.; Mermitt, M. B.; Thomsen, C.; Pellicciari, R. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 196–199. (j) Midura, W. H.; Sobczak, A.; Paluch, P. *Tetrahedron Lett.* **2013**, *54*, 223–226.

- (7) Charette, A. B.; Bouchard, J.-E. *Can. J. Chem.* **2005**, *83*, 533–542.
- (8) Lindsay, V. N. G.; Fiset, D.; Gritsch, P. J.; Azzi, S.; Charette, A. B. *J. Am. Chem. Soc.* **2013**, *135*, 1463–1470.
- (9) (a) Ferrand, Y.; Maux, P. L.; Simonneaux, G. *Org. Lett.* **2004**, *6*, 3211–3213. (b) Paul-Roth, C.; Montigny, F. D.; Rethoré, G.; Simonneaux, G.; Gulea, M.; Masson, S. *J. Mol. Catal. A: Chem.* **2003**, *201*, 79–91.
- (10) (a) Abu-Elfotouh, A.-M.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. *Angew. Chem., Int. Ed.* **2010**, *49*, 8439–8443. (b) Chanthamath, S.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. *Chem. Commun.* **2012**, *48*, 7750–7752. (c) Chanthamath, S.; Thongjareun, S.; Shibatomi, K.; Iwasa, S. *Tetrahedron Lett.* **2012**, *53*, 4862–4865. (d) Abu-Elfotouh, A.-M.; Nguyen, D. P. T.; Chanthamath, S.; Phomkeona, K.; Shibatomi, K.; Iwasa, S. *Adv. Synth. Catal.* **2012**, *354*, 3435–3439. (e) Chanthamath, S.; Nguyen, D. T.; Shibatomi, K.; Iwasa, S. *Org. Lett.* **2013**, *15*, 772–775. (f) Chanthamath, S.; Takaki, S.; Shibatomi, K.; Iwasa, S. *Angew. Chem., Int. Ed.* **2013**, *52*, 5818–5821.
- (11) Absolute configuration of **7o** was determined to be (1*R*,2*R*) by comparing the reported specific optical rotation: $[\alpha]_{\text{D}}^{25} -55.7$ (*c* 1.00, CHCl₃), Lit. $[\alpha]_{\text{D}}^{20} -50.1$ (*c* 1.20, CHCl₃) for 1*R*,2*R*-isomer, see: Krawczyk, H.; Wasek, K.; Kedzia, J. *Synthesis* **2009**, *9*, 1473–1476.
- (12) The reduction of the optically active cyclopropylphosphonate **7p** was performed using the procedure by Midura; see: Reference 3.
- (13) The enantioselectivity was determined by benzoylation using benzoyl chloride (see Supporting Information).
- (14) Hah, J. H.; Gil, J. M.; Oh, D. Y. *Tetrahedron Lett.* **1999**, *40*, 8235–8238.